230 related articles for article (PubMed ID: 26768834)
1. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
[TBL] [Abstract][Full Text] [Related]
2. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.
Davidson B; Abeler VM; Hellesylt E; Holth A; Shih IeM; Skeie-Jensen T; Chen L; Yang Y; Wang TL
Gynecol Oncol; 2013 Feb; 128(2):349-55. PubMed ID: 23178314
[TBL] [Abstract][Full Text] [Related]
3. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
4. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation.
Yilmaz A; Rush DS; Soslow RA
Am J Surg Pathol; 2002 Sep; 26(9):1142-50. PubMed ID: 12218570
[TBL] [Abstract][Full Text] [Related]
5. Gene expression signatures of primary and metastatic uterine leiomyosarcoma.
Davidson B; Abeler VM; Førsund M; Holth A; Yang Y; Kobayashi Y; Chen L; Kristensen GB; Shih IeM; Wang TL
Hum Pathol; 2014 Apr; 45(4):691-700. PubMed ID: 24485798
[TBL] [Abstract][Full Text] [Related]
6. Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.
Davidson B; Hellesylt E; Holth A; Danielsen HE; Skeie-Jensen T; Katz B
Virchows Arch; 2017 Sep; 471(3):355-362. PubMed ID: 28643014
[TBL] [Abstract][Full Text] [Related]
7. Molecular characteristics of uterine sarcomas.
Davidson B; Micci F
Expert Rev Mol Diagn; 2017 May; 17(5):515-522. PubMed ID: 28335657
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.
Goff BA; Rice LW; Fleischhacker D; Muntz HG; Falkenberry SS; Nikrui N; Fuller AF
Gynecol Oncol; 1993 Jul; 50(1):105-9. PubMed ID: 8349151
[TBL] [Abstract][Full Text] [Related]
9. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Tumour Biol; 2011 Jun; 32(3):451-9. PubMed ID: 21161468
[TBL] [Abstract][Full Text] [Related]
11. Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry.
Mills AM; Beck AH; Montgomery KD; Zhu SX; Espinosa I; Lee CH; Subramanian S; Fletcher CD; van de Rijn M; West RB
Am J Surg Pathol; 2011 Apr; 35(4):583-9. PubMed ID: 21412072
[TBL] [Abstract][Full Text] [Related]
12. Novel High-grade Endometrial Stromal Sarcoma: A Morphologic Mimicker of Myxoid Leiomyosarcoma.
Hoang LN; Aneja A; Conlon N; Delair DF; Middha S; Benayed R; Hensley ML; Park KJ; Hollmann TJ; Hameed MR; Antonescu CR; Soslow RA; Chiang S
Am J Surg Pathol; 2017 Jan; 41(1):12-24. PubMed ID: 27631520
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement.
Lee CH; Ali RH; Rouzbahman M; Marino-Enriquez A; Zhu M; Guo X; Brunner AL; Chiang S; Leung S; Nelnyk N; Huntsman DG; Blake Gilks C; Nielsen TO; Dal Cin P; van de Rijn M; Oliva E; Fletcher JA; Nucci MR
Am J Surg Pathol; 2012 Oct; 36(10):1562-70. PubMed ID: 22982899
[TBL] [Abstract][Full Text] [Related]
14. Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review.
Horng HC; Wen KC; Wang PH; Chen YJ; Yen MS; Ng HT;
Taiwan J Obstet Gynecol; 2016 Aug; 55(4):472-9. PubMed ID: 27590366
[TBL] [Abstract][Full Text] [Related]
15. Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement.
D'Angelo E; Ali RH; Espinosa I; Lee CH; Huntsman DG; Gilks B; Prat J
Am J Surg Pathol; 2013 Apr; 37(4):514-21. PubMed ID: 23211293
[TBL] [Abstract][Full Text] [Related]
16. Extrapelvic Metastases in Endometrial Stromal Sarcomas: A Clinicopathological Review With Immunohistochemical and Molecular Characterization.
Baniak N; Adams S; Lee CH; Chibbar R; Kanthan R
Int J Surg Pathol; 2019 Apr; 27(2):208-215. PubMed ID: 30124116
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
Wang F; Dai X; Chen H; Hu X; Wang Y
BMC Cancer; 2022 Oct; 22(1):1050. PubMed ID: 36207687
[TBL] [Abstract][Full Text] [Related]
18. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.
Huss A; Klar M; Hasanov MF; Juhasz-Böss I; Bossart M
Arch Gynecol Obstet; 2023 Mar; 307(3):927-935. PubMed ID: 35780401
[TBL] [Abstract][Full Text] [Related]
20. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma.
Rush DS; Tan J; Baergen RN; Soslow RA
Am J Surg Pathol; 2001 Feb; 25(2):253-8. PubMed ID: 11176075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
